On January 28, 2026 Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, reported a new contract with its valued and long-standing client, Numab Therapeutics AG ("Numab Therapeutics").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This project reflects the continued application of Physiomics’ modelling expertise across Numab Therapeutics’ pipeline to accelerate the development of innovative therapies, building further on the already well-established relationship.
Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract, Physiomics will develop a pharmacokinetic-pharmacodynamic (PK/PD) model to inform the Target Candidate Profile of a key asset in Numab Therapeutics’ Immunology and Inflammation pipeline. The modelling work is intended to support data-driven decision-making at an early stage of development and is expected to commence imminently, with completion anticipated within Q2 2026.
Dr Peter Sargent, CEO of Physiomics, commented:
"We are delighted to continue our collaboration with Numab Therapeutics and to have the opportunity to contribute further insights across its promising pipeline. In particular, this work allows us to support earlier research and development decisions through quantitative, data-driven approaches, helping to shape candidate profiles at a critical stage and thus streamlining drug development journeys."
(Press release, Physiomics, JAN 28, 2026, View Source [SID1234662329])